SAR 351034
Alternative Names: SAR3504; SAR351034Latest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in France
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in France